Please enable JavaScript to continue using this application.

Compare $IRD vs $XFOR | Chartloom

Compare

$IRD vs $XFOR

Opus Genetics Inc · X4 Pharmaceuticals Inc

IRD

Opus Genetics Inc

XFOR

X4 Pharmaceuticals Inc

Compare $IRD vs $XFOR

Comparing Opus Genetics Inc and X4 Pharmaceuticals Inc

IRDOpus Genetics Inc

XFORX4 Pharmaceuticals Inc

IRDOpus Genetics Inc

Market cap

$384M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

28.68x

Rev growth (TTM)

-36.1%

YTD performance

119.3%

52W performance

126.8%

FCF yield

-10.6%

XFORX4 Pharmaceuticals Inc

Market cap

$274M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

28.09x

Rev growth (TTM)

-51.6%

YTD performance

-25.2%

52W performance

-12.3%

FCF yield

-32.3%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

IRD

XFOR

Detailed metrics comparison

IRD

Opus Genetics Inc

XFOR

X4 Pharmaceuticals Inc

Market Cap

IRD$384M

XFOR$274M

Enterprise Value

IRD$331M

XFOR$156M

Price

IRD$4.65

XFOR$2.91

P/E Ratio

IRDN/A

XFORN/A

P/S Ratio

IRD38.96x

XFOR17.32x

EV/Sales

IRD33.62x

XFOR9.85x

EV/EBITDA

IRD11.29x

XFOR0.00x

P/B Ratio

IRD24.83x

XFOR1.81x

P/FCF Ratio

IRDN/A

XFORN/A

EV/FCF

IRD-8.15x

XFOR-1.76x

PEG Ratio

IRDN/A

XFORN/A

Forward P/E (NTM)

IRDN/A

XFORN/A

Forward P/S (NTM)

IRD28.68x

XFOR28.09x

Revenue (TTM)

IRD$10M

XFOR$16M

Revenue Growth (YoY)

IRD-36.1%

XFOR-51.6%

Forward Rev Growth

IRD8.5%

XFOR-27.7%

Gross Margin (TTM)

IRD0.0%

XFOR81.5%

Operating Margin (TTM)

IRD0.0%

XFOR0.0%

EBITDA Margin (TTM)

IRD-504.8%

XFOR-544.2%

Net Margin (TTM)

IRD-1091.8%

XFOR-568.8%

FCF Margin (TTM)

IRD-412.6%

XFOR-560.0%

Net Income (TTM)

IRD$-108M

XFOR$-90M

FCF (TTM)

IRD$-41M

XFOR$-89M

EPS (TTM)

IRD-$1.13

XFOR-$0.71

ROE (TTM)

IRD-31635.0%

XFOR-6305.0%

ROA (TTM)

IRD-17489.0%

XFOR-3689.0%

ROIC (TTM)

IRD-30100.0%

XFOR-4109.0%

Cash

IRD$89M

XFOR$195M

Debt

IRD$36M

XFOR$77M

Net Cash/Debt

IRD$53M

XFOR$118M

Current Ratio (TTM)

IRD12.19x

XFOR11.30x

Quick Ratio (TTM)

IRD11.87x

XFOR10.87x

Debt/Equity (TTM)

IRD0.07x

XFOR0.49x

Debt/Assets (TTM)

IRD0.0%

XFOR0.0%

Interest Coverage (TTM)

IRDN/A

XFORN/A

Net Debt/EBITDA (TTM)

IRD0.00x

XFOR0.00x

Beta

IRD0.77

XFOR0.50

52W Performance

IRD126.8%

XFOR-12.3%

YTD Performance

IRD119.3%

XFOR-25.2%

% from 52W High

IRD-34.2%

XFOR-39.8%

% from 52W Low

IRD173.5%

XFOR7.8%

Asset Turnover (TTM)

IRD0.16x

XFOR0.06x

FCF Yield (TTM)

IRD-10.6%

XFOR-32.3%

Earnings Yield (TTM)

IRD-28.0%

XFOR-32.8%

Dividend Yield (TTM)

IRDN/A

XFORN/A

Rule of 40

IRD-448.7

XFOR-611.6

EV/GP/RG

IRDN/A

XFORN/A

Ticker research

View IRD research View XFOR research

Metric	IRD Opus Genetics Inc	XFOR X4 Pharmaceuticals Inc
Market & Valuation
Market Cap	$384M	$274M
Enterprise Value	$331M	$156M
Price	$4.65	$2.91
P/E Ratio	N/A	N/A
P/S Ratio	38.96x	17.32x
EV/Sales	33.62x	9.85x
EV/EBITDA	11.29x	0.00x
P/B Ratio	24.83x	1.81x
P/FCF Ratio	N/A	N/A
EV/FCF	-8.15x	-1.76x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	28.68x	28.09x
Revenue & Growth
Revenue (TTM)	$10M	$16M
Revenue Growth (YoY)	-36.1%	-51.6%
Forward Rev Growth	8.5%	-27.7%
Profitability
Gross Margin (TTM)	0.0%	81.5%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-504.8%	-544.2%
Net Margin (TTM)	-1091.8%	-568.8%
FCF Margin (TTM)	-412.6%	-560.0%
Net Income (TTM)	$-108M	$-90M
FCF (TTM)	$-41M	$-89M
EPS (TTM)	-$1.13	-$0.71
ROE (TTM)	-31635.0%	-6305.0%
ROA (TTM)	-17489.0%	-3689.0%
ROIC (TTM)	-30100.0%	-4109.0%
Financial Health
Cash	$89M	$195M
Debt	$36M	$77M
Net Cash/Debt	$53M	$118M
Current Ratio (TTM)	12.19x	11.30x
Quick Ratio (TTM)	11.87x	10.87x
Debt/Equity (TTM)	0.07x	0.49x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.77	0.50
52W Performance	126.8%	-12.3%
YTD Performance	119.3%	-25.2%
% from 52W High	-34.2%	-39.8%
% from 52W Low	173.5%	7.8%
Efficiency & Yields
Asset Turnover (TTM)	0.16x	0.06x
FCF Yield (TTM)	-10.6%	-32.3%
Earnings Yield (TTM)	-28.0%	-32.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-448.7	-611.6
EV/GP/RG	N/A	N/A
Ticker research	View IRD research	View XFOR research

Valuation

P/S Ratio

XFOR

17.32x

IRD

38.96x

EV/FCF

IRD

-8.15x

XFOR

-1.76x

Growth & revenue

Revenue Growth TTM

IRD

-36.1%

XFOR

-51.6%

Forward Revenue Growth

IRD

8.5%

XFOR

-27.7%

Profitability & performance

Gross Margin

XFOR

81.5%

IRD

0.0%

ROE

XFOR

-6305.0%

IRD

-31635.0%

FCF Yield %

IRD

-10.6%

XFOR

-32.3%

52-Week Performance

IRD

126.8%

XFOR

-12.3%

Detailed metrics comparison

IRD

Opus Genetics Inc

XFOR

X4 Pharmaceuticals Inc

Market Cap

IRD$384M

XFOR$274M

Enterprise Value

IRD$331M

XFOR$156M

Price

IRD$4.65

XFOR$2.91

P/E Ratio

IRDN/A

XFORN/A

P/S Ratio

IRD38.96x

XFOR17.32x

EV/Sales

IRD33.62x

XFOR9.85x

EV/EBITDA

IRD11.29x

XFOR0.00x

P/B Ratio

IRD24.83x

XFOR1.81x

P/FCF Ratio

IRDN/A

XFORN/A

EV/FCF

IRD-8.15x

XFOR-1.76x

PEG Ratio

IRDN/A

XFORN/A

Forward P/E (NTM)

IRDN/A

XFORN/A

Forward P/S (NTM)

IRD28.68x

XFOR28.09x

Revenue (TTM)

IRD$10M

XFOR$16M

Revenue Growth (YoY)

IRD-36.1%

XFOR-51.6%

Forward Rev Growth

IRD8.5%

XFOR-27.7%

Gross Margin (TTM)

IRD0.0%

XFOR81.5%

Operating Margin (TTM)

IRD0.0%

XFOR0.0%

EBITDA Margin (TTM)

IRD-504.8%

XFOR-544.2%

Net Margin (TTM)

IRD-1091.8%

XFOR-568.8%

FCF Margin (TTM)

IRD-412.6%

XFOR-560.0%

Net Income (TTM)

IRD$-108M

XFOR$-90M

FCF (TTM)

IRD$-41M

XFOR$-89M

EPS (TTM)

IRD-$1.13

XFOR-$0.71

ROE (TTM)

IRD-31635.0%

XFOR-6305.0%

ROA (TTM)

IRD-17489.0%

XFOR-3689.0%

ROIC (TTM)

IRD-30100.0%

XFOR-4109.0%

Cash

IRD$89M

XFOR$195M

Debt

IRD$36M

XFOR$77M

Net Cash/Debt

IRD$53M

XFOR$118M

Current Ratio (TTM)

IRD12.19x

XFOR11.30x

Quick Ratio (TTM)

IRD11.87x

XFOR10.87x

Debt/Equity (TTM)

IRD0.07x

XFOR0.49x

Debt/Assets (TTM)

IRD0.0%

XFOR0.0%

Interest Coverage (TTM)

IRDN/A

XFORN/A

Net Debt/EBITDA (TTM)

IRD0.00x

XFOR0.00x

Beta

IRD0.77

XFOR0.50

52W Performance

IRD126.8%

XFOR-12.3%

YTD Performance

IRD119.3%

XFOR-25.2%

% from 52W High

IRD-34.2%

XFOR-39.8%

% from 52W Low

IRD173.5%

XFOR7.8%

Asset Turnover (TTM)

IRD0.16x

XFOR0.06x

FCF Yield (TTM)

IRD-10.6%

XFOR-32.3%

Earnings Yield (TTM)

IRD-28.0%

XFOR-32.8%

Dividend Yield (TTM)

IRDN/A

XFORN/A

Rule of 40

IRD-448.7

XFOR-611.6

EV/GP/RG

IRDN/A

XFORN/A

Ticker research

View IRD research View XFOR research

Metric	IRD Opus Genetics Inc	XFOR X4 Pharmaceuticals Inc
Market & Valuation
Market Cap	$384M	$274M
Enterprise Value	$331M	$156M
Price	$4.65	$2.91
P/E Ratio	N/A	N/A
P/S Ratio	38.96x	17.32x
EV/Sales	33.62x	9.85x
EV/EBITDA	11.29x	0.00x
P/B Ratio	24.83x	1.81x
P/FCF Ratio	N/A	N/A
EV/FCF	-8.15x	-1.76x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	28.68x	28.09x
Revenue & Growth
Revenue (TTM)	$10M	$16M
Revenue Growth (YoY)	-36.1%	-51.6%
Forward Rev Growth	8.5%	-27.7%
Profitability
Gross Margin (TTM)	0.0%	81.5%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-504.8%	-544.2%
Net Margin (TTM)	-1091.8%	-568.8%
FCF Margin (TTM)	-412.6%	-560.0%
Net Income (TTM)	$-108M	$-90M
FCF (TTM)	$-41M	$-89M
EPS (TTM)	-$1.13	-$0.71
ROE (TTM)	-31635.0%	-6305.0%
ROA (TTM)	-17489.0%	-3689.0%
ROIC (TTM)	-30100.0%	-4109.0%
Financial Health
Cash	$89M	$195M
Debt	$36M	$77M
Net Cash/Debt	$53M	$118M
Current Ratio (TTM)	12.19x	11.30x
Quick Ratio (TTM)	11.87x	10.87x
Debt/Equity (TTM)	0.07x	0.49x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.77	0.50
52W Performance	126.8%	-12.3%
YTD Performance	119.3%	-25.2%
% from 52W High	-34.2%	-39.8%
% from 52W Low	173.5%	7.8%
Efficiency & Yields
Asset Turnover (TTM)	0.16x	0.06x
FCF Yield (TTM)	-10.6%	-32.3%
Earnings Yield (TTM)	-28.0%	-32.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-448.7	-611.6
EV/GP/RG	N/A	N/A
Ticker research	View IRD research	View XFOR research